BSE Live
Mar 11, 16:00Prev. Close
2.02
Open Price
2.02
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2.02 (1876)
NSE Live
Mar 11, 15:32Prev. Close
1.75
Open Price
1.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Celestial Biolabs (in Rs. Cr.) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | -0.57 | -0.41 | -0.17 | -99.75 | 1.40 | |
| Net CashFlow From Operating Activities | -0.35 | -0.28 | -0.03 | -3.06 | 16.65 | |
| Net Cash Used In Investing Activities | -0.01 | 0.00 | 0.00 | 4.09 | -18.66 | |
| Net Cash Used From Financing Activities | 0.37 | 0.26 | 0.05 | -1.07 | 2.05 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 0.02 | -0.02 | 0.01 | -0.04 | 0.04 | |
| Cash And Cash Equivalents Begin of Year | 0.00 | 0.02 | 0.01 | 0.05 | 0.01 | |
| Cash And Cash Equivalents End Of Year | 0.02 | 0.00 | 0.02 | 0.01 | 0.05 |
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
18.03.2026
17.03.2026
Zydus, Lupin sign agreement to co‑market weight-loss semaglutide injection in India
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth